Zobrazeno 1 - 10
of 47
pro vyhledávání: '"M H Weisman"'
Autor:
D E, Furst, E C, Keystone, B, Kirkham, A, Kavanaugh, R, Fleischmann, P, Mease, F C, Breedveld, J S, Smolen, J R, Kalden, G R, Burmester, J, Braun, P, Emery, K, Winthrop, B, Bresnihan, F, De Benedetti, T, Dörner, A, Gibofsky, M H, Schiff, J, Sieper, N, Singer, P L C M, Van Riel, M E, Weinblatt, M H, Weisman
Publikováno v:
Annals of the Rheumatic Diseases, 67 Suppl 3, 3, pp. iii2-25
Annals of the Rheumatic Diseases, 67 Suppl 3, iii2-25
Annals of the Rheumatic Diseases, 67 Suppl 3, iii2-25
Contains fulltext : 70534.pdf (Publisher’s version ) (Closed access)
Autor:
Kenneth C. Kalunian, G. D. Braunstein, M. H. Weisman, Shuntaro Shinada, C. Gordon, Daniel J. Wallace, L. Forbess
Publikováno v:
Rheumatology. 47:334-338
Objectives. Androgen deficiency has been associated with the development of systemic lupus erythematosus (SLE). The aim of this study was to test the efficacy of testosterone patches vs placebo in female SLE patients with baseline mild-to- moderate d
Autor:
D S Hallegua, M H Weisman
Publikováno v:
Annals of the Rheumatic Diseases. 61:960-967
To review publications relating to the blocking of interleukin 1 (IL1) as a strategy for treating human disease, ranging from rheumatoid arthritis (RA) to Alzheimer's disease.The National Library of Medicine's PubMed database was searched for article
Autor:
D E Furst, E C Keystone, J Braun, F C Breedveld, G R Burmester, F De Benedetti, T Dörner, P Emery, R Fleischmann, A Gibofsky, J R Kalden, A Kavanaugh, B Kirkham, P Mease, J Sieper, N G Singer, J S Smolen, P L C M Van Riel, M H Weisman, K Winthrop
Publikováno v:
Annals of the Rheumatic Diseases, 71, 2-45
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::651ea16f100c8c2e17c84fac5824eb73
https://hdl.handle.net/1887/101962
https://hdl.handle.net/1887/101962
Intravenous thrombolytic therapy has become standard treatment for acute myocardial infarction (AMI). We describe three patients with long-standing seropositive rheumatoid arthritis (RA) on chronic corticosteroid therapy who experienced very early (1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2304ce7bc0753ab3813013511911a7c
https://europepmc.org/articles/PMC6656063/
https://europepmc.org/articles/PMC6656063/
Autor:
D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J Sieper, P Emery, E C Keystone, M H Schiff, P Mease, P L C M van Riel, R Fleischmann, M H Weisman, M E Weinblatt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbf34c6475f83e1da65da4778c461e9e
https://europepmc.org/articles/PMC2095281/
https://europepmc.org/articles/PMC2095281/
Autor:
D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, P Emery, E C Keystone, M H Schiff, P L C M van Riel, M E Weinblatt, M H Weisman
Publikováno v:
Annals of the rheumatic diseases. 65
Autor:
Haralampos M. Moutsopoulos, Stefano Bombardieri, Claudio Vitali, Steven E. Carsons, S R Pillemer, E L Alexander, Norman Talal, Roland Jonsson, M H Weisman, P C Fox, Troy E. Daniels, Stuart S. Kassan, Robert I. Fox
Publikováno v:
Annals of the rheumatic diseases. 61(6)
Classification criteria for Sjogren's syndrome (SS) were developed and validated between 1989 and 1996 by the European Study Group on Classification Criteria for SS, and broadly accepted. These have been re-examined by consensus group members, who ha
Publikováno v:
The Journal of rheumatology. 28(9)
To investigate the relative contributions of disease status, helplessness, and depression to fatigue in patients with systemic lupus erythematosus (SLE) in a path-analytic framework.The disease status of 81 patients with SLE was evaluated by a clinic
Autor:
R A, Furie, J M, Cash, M E, Cronin, R S, Katz, M H, Weisman, C, Aranow, M R, Liebling, N P, Hudson, C M, Berner, S, Coutts, H A, de Haan
Publikováno v:
The Journal of rheumatology. 28(2)
LJP 394 is a novel therapy under development for the treatment of systemic lupus erythematosus (SLE). We investigated the optimal LJP 394 dosing regimen required to maximally reduce serum dsDNA antibodies. We also evaluated the safety and tolerabilit